Experimental drug navtemadlin tested for glioblastoma

NCT ID NCT03107780

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested the drug navtemadlin in 32 adults with glioblastoma, a type of brain cancer. The study aimed to find the best dose and check side effects, both for newly diagnosed and recurrent cases. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: navtemadlin (also known as AMG 232 or KRT 232)
What this could lead to: If successful, this could point toward a new treatment option for glioblastoma, especially for patients with unmethylated MGMT promoters.
What could go wrong: This was a very early (Phase I) trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOSARCOMA MGMT-UNMETHYLATED GLIOBLASTOMA RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States
UPMC-Shadyside Hospital

Pittsburgh, Pennsylvania, 15232, United States
University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233, United States
University of Pennsylvania/Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232, United States
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.